Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03301220




Registration number
NCT03301220
Ethics application status
Date submitted
29/09/2017
Date registered
4/10/2017
Date last updated
6/12/2024

Titles & IDs
Public title
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Scientific title
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Secondary ID [1] 0 0
54767414SMM3001
Secondary ID [2] 0 0
CR108172
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Smoldering Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types
Cancer 0 0 0 0
Myeloma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab SC: daratumumab + rHuPH20

No intervention: Arm A: Active Monitoring - Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.

Experimental: Arm B: Daratumumab SC - Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.


Treatment: Drugs: Daratumumab SC: daratumumab + rHuPH20
Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years)
Secondary outcome [1] 0 0
Time to Biochemical or Diagnostic (SLiM-CRAB) Progression
Timepoint [1] 0 0
Up to biochemical or diagnostic progression (up to approximately 8 years)
Secondary outcome [2] 0 0
Overall Response Rate (ORR)
Timepoint [2] 0 0
Up to approximately 8 years
Secondary outcome [3] 0 0
Complete Response (CR) Rate
Timepoint [3] 0 0
Up to approximately 8 years
Secondary outcome [4] 0 0
Time to First-Line Treatment for Multiple Myeloma (MM)
Timepoint [4] 0 0
Post-progressive disease (PD) follow-up, every 6 months until end of study (up to approximately 8 years)
Secondary outcome [5] 0 0
Progression-Free Survival on First-Line Treatment for MM (PFS2)
Timepoint [5] 0 0
Post-PD follow-up, every 6 months until end of study (up to approximately 8 years)
Secondary outcome [6] 0 0
Overall Survival (OS)
Timepoint [6] 0 0
Throughout study, and at least every 3 months until PD; post-PD, every 6 months until end of study (up to approximately 8 years)
Secondary outcome [7] 0 0
Percentage of Participants who Progress to MM With Adverse Prognostic Features
Timepoint [7] 0 0
At screening and PD (up to approximately 8 years)
Secondary outcome [8] 0 0
Serum Daratumumab Pharmacokinetic (PK) Concentration
Timepoint [8] 0 0
Cycles 1 and 3: Day 1 predose, and Day 4 postdose; Cycles 5, 7, 12, and 24: Day 1 predose; end of the treatment (EOT: 28 days after the last daratumumab dose); and 8 weeks after the last daratumumab dose (up to approximately 3 years and 8 weeks)
Secondary outcome [9] 0 0
Maximum Observed Concentration (Cmax) of Daratumumab
Timepoint [9] 0 0
Cycles 1 and 3: Day 1 predose, and Day 4 postdose; Cycles 5, 7, 12, and 24: Day 1 predose; end of the treatment (EOT: 28 days after the last daratumumab dose); and 8 weeks after the last daratumumab dose (up to approximately 3 years and 8 weeks)
Secondary outcome [10] 0 0
Minimum Observed Concentration (Cmin) of Daratumumab
Timepoint [10] 0 0
Cycles 1 and 3: Day 1 predose, and Day 4 postdose; Cycles 5, 7, 12, and 24: Day 1 predose; end of the treatment (EOT: 28 days after the last daratumumab dose); and 8 weeks after the last daratumumab dose (up to approximately 3 years and 8 weeks)
Secondary outcome [11] 0 0
Number of Participants With Anti-daratumumab Antibodies
Timepoint [11] 0 0
Cycles 1,3,5,7,12, and 24: Predose on Day 1; end of treatment (28 days after the last daratumumab dose), and 8 weeks after the last daratumumab dose (up to approximately 3 years and 8 weeks)
Secondary outcome [12] 0 0
Number of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies
Timepoint [12] 0 0
Cycles 1,3,5,7,12, and 24: Predose on Day 1; end of treatment (28 days after the last daratumumab dose), and 8 weeks after the last daratumumab dose (up to approximately 3 years and 8 weeks)
Secondary outcome [13] 0 0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
Timepoint [13] 0 0
Baseline, Weeks 12, 24, and 60, every year until end of treatment (EOT)/active monitoring, pre-PD follow-up (every year until end of study or PD), PD, and Months 3, 6, 12, and 18 post-PD (up to approximately 8 years)
Secondary outcome [14] 0 0
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale
Timepoint [14] 0 0
Baseline, Weeks 12, 24, and 60, every year until end of treatment (EOT)/active monitoring, pre-PD follow-up (every year until end of study or PD), PD, and Months 3, 6, 12, and 18 post-PD (up to approximately 8 years)
Secondary outcome [15] 0 0
Change From Baseline in European Quality (EuroQoL) 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire
Timepoint [15] 0 0
Baseline, Weeks 12, 24, and 60, every year until end of treatment (EOT)/active monitoring, pre-PD follow-up (every year until end of study or PD), PD, and Months 3, 6, 12, and 18 post-PD (up to approximately 8 years)
Secondary outcome [16] 0 0
Duration of Response
Timepoint [16] 0 0
From the date of initial documentation of a response to the date of first documented evidence of PD (up to approximately 8 years)
Secondary outcome [17] 0 0
Time to Response
Timepoint [17] 0 0
Up to End of Treatment (up to approximately 39 cycles [each cycle of 28 days] or 36 months, whichever occurs first)

Eligibility
Key inclusion criteria
* Diagnosis of high risk smoldering multiple myeloma (SMM) (per International Myeloma Working Group [IMWG] criteria) for less than or equal to (<=) 5 years with measurable disease at the time of randomization, defined as serum M protein greater than or equal to (>=) 10 gram per liter (g/L) or urine M protein >= 200 milligram per 24 hours (mg/24 hours) or involved serum free light chain (FLC) >=100 milligram per liter (mg/L) and abnormal serum FLC ratio
* Clonal bone marrow plasma cells (BMPCs) >= 10 percentage (%); and at least 1 of the following risk factors; Serum M protein >= 30 g/L, immunoglobulin (Ig)A SMM, immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes (only IgA, IgM, and IgG should be considered in determination for immunoparesis; IgD and IgE are not considered in this assessment), serum involved: uninvolved FLC ratio >= 8 and less than (<) 100, or clonal BMPCs greater than (>) 50% to <60% with measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
* Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use highly effective method of contraception
* A woman of childbearing potential must have a negative serum or urine pregnancy test at screening within 14 days prior to randomization
* During the study and for 3 months after receiving the last dose of daratumumab, a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Multiple myeloma (MM), requiring treatment, defined by any of the following:

1. Bone lesions (1 or more osteolytic lesions on low-dose whole body computed tomography [LDCT], positron-emission tomography with computed tomography [PET-CT] or CT). Participants who have benign/post-traumatic bone lesions visible on screening images as well as previous imaging, may be considered for inclusion. Details (diagnosis, location, duration) on benign/post-traumatic pre-existing bone lesions that can be seen on the screening images (example [eg.], old fractures) and were also present on previous imaging are to be reported in the case report form (CRF)
2. Hypercalcemia (serum calcium greater than [>]0.25 millimoles per liter [mmol/L] [>1 milligram per deciliter {mg/dL}] higher than upper limit of normal [ULN] or >2.75 mmol/L [>11 mg/dL]). Participants who have clinically stable hypercalcemia attributable to a disease other than multiple myeloma (eg, hyperparathyroidism) may be considered for inclusion after a case by case review by the medical monitor
3. Renal insufficiency, preferably determined by creatinine clearance less than (<)40 milliliter per minute (mL/min) measured or estimated using the Modification of Diet in Renal Disease (MDRD), or serum creatinine >177 micromole per liter (µmol/L). Participants who have clinically stable renal insufficiency attributable to a disease other than multiple myeloma (eg, glomerulonephritis) may be considered for inclusion after a case by case review by the medical monitor
4. Anemia, defined as hemoglobin <10 gram per deciliter (g/dL) or >2 g/dL below lower limit of normal or both; transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted. Participants who have clinically stable anemia attributable to a disease other than multiple myeloma (eg, thalassemia, vitamin B12 deficiency, iron deficiency) may be considered for inclusion after a case by case review by the medical monitor
5. Clonal BMPC percentage >=60%
6. Serum FLC ratio (involved:uninvolved) >=100 (the involved FLC must be >=100 mg/L)
7. More than 1 focal lesion >=5 millimeter (mm) in diameter by magnetic resonance imaging (MRI)
* Primary systemic amyloid light-chain (AL) (immunoglobulin light chain) amyloidosis
* Exposure to any of the following:

1. Prior exposure to daratumumab or prior exposure to other anti-Cluster of Differentiation 38 (anti-CD38) therapies
2. Prior exposure to approved or investigational treatments for SMM or MM (including but not limited to conventional chemotherapies, immunomodulatory agent [IMiDs], or proteasome inhibitor [PIs]). Stable standard dosing of bisphosphonate and denosumab as indicated for osteoporosis is acceptable
3. Exposure to investigational drug (including investigational vaccines) or invasive investigational medical device for any indication within 4 weeks or 5 half-lives, whichever is longer, before Cycle 1, Day 1
4. Ongoing treatment with corticosteroids with a dose >10 milligram (mg) prednisone or equivalent per day at the time of randomization; or >280 mg cumulative prednisone dose or equivalent for any 4-week period in the year prior to randomization
5. Ongoing treatment with other monoclonal antibodies (eg, infliximab, rituximab), immunomodulators (eg, abatacept, methotrexate, azathioprine, cyclosporine) or other treatments that are likely to interfere with the study procedures or results
* Received treatment (chemotherapy, surgery, et cetera [etc]) for a malignancy (other than SMM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion), which is considered cured with minimal risk of recurrence within 3 years
* Medical or psychiatric condition or disease (for example, active systemic disease [including presence of auto-antibodies], uncontrolled diabetes) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
* Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products (including dairy allergy)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/12/2025
Actual
Sample size
Target
Accrual to date
Final
390
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [2] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment hospital [3] 0 0
The Perth Blood Institute - West Perth
Recruitment hospital [4] 0 0
Queen Elizabeth Hospital - Woodville
Recruitment postcode(s) [1] 0 0
3150 or 3084 - Heidelberg
Recruitment postcode(s) [2] 0 0
2298 - Waratah
Recruitment postcode(s) [3] 0 0
6005 - West Perth
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Louisiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad de Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Cordoba
Country [22] 0 0
Argentina
State/province [22] 0 0
La Plata
Country [23] 0 0
Argentina
State/province [23] 0 0
Rosario
Country [24] 0 0
Belgium
State/province [24] 0 0
Antwerpen
Country [25] 0 0
Belgium
State/province [25] 0 0
Brugge
Country [26] 0 0
Belgium
State/province [26] 0 0
Brussel
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Belgium
State/province [28] 0 0
Hasselt
Country [29] 0 0
Belgium
State/province [29] 0 0
Kortrijk
Country [30] 0 0
Brazil
State/province [30] 0 0
Florianopolis
Country [31] 0 0
Brazil
State/province [31] 0 0
Goiania
Country [32] 0 0
Brazil
State/province [32] 0 0
Joinville
Country [33] 0 0
Brazil
State/province [33] 0 0
Porto Alegre
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio de Janeiro
Country [35] 0 0
Brazil
State/province [35] 0 0
Salvador
Country [36] 0 0
Brazil
State/province [36] 0 0
Sao Jose do Rio Preto
Country [37] 0 0
Brazil
State/province [37] 0 0
Sao Paulo
Country [38] 0 0
Brazil
State/province [38] 0 0
São Paulo
Country [39] 0 0
Canada
State/province [39] 0 0
Alberta
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Czechia
State/province [41] 0 0
Hradec Kralove
Country [42] 0 0
Czechia
State/province [42] 0 0
Ostrava
Country [43] 0 0
Czechia
State/province [43] 0 0
Plzen
Country [44] 0 0
Czechia
State/province [44] 0 0
Praha 2
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus N.
Country [46] 0 0
Denmark
State/province [46] 0 0
Copenhagen
Country [47] 0 0
Denmark
State/province [47] 0 0
Odense C
Country [48] 0 0
Denmark
State/province [48] 0 0
Ålborg
Country [49] 0 0
France
State/province [49] 0 0
Limoges
Country [50] 0 0
France
State/province [50] 0 0
Nantes cedex 01
Country [51] 0 0
France
State/province [51] 0 0
Pessac cedex
Country [52] 0 0
France
State/province [52] 0 0
Pierre Benite cedex
Country [53] 0 0
France
State/province [53] 0 0
Poitiers
Country [54] 0 0
France
State/province [54] 0 0
Rennes
Country [55] 0 0
France
State/province [55] 0 0
Tours Cedex 9
Country [56] 0 0
Germany
State/province [56] 0 0
Berlin
Country [57] 0 0
Germany
State/province [57] 0 0
Hamm
Country [58] 0 0
Germany
State/province [58] 0 0
Heidelberg
Country [59] 0 0
Germany
State/province [59] 0 0
Muenster
Country [60] 0 0
Germany
State/province [60] 0 0
Tübingen
Country [61] 0 0
Germany
State/province [61] 0 0
Ulm
Country [62] 0 0
Greece
State/province [62] 0 0
Athens Attica
Country [63] 0 0
Hungary
State/province [63] 0 0
Budapest N/a
Country [64] 0 0
Hungary
State/province [64] 0 0
Budapest
Country [65] 0 0
Hungary
State/province [65] 0 0
Debrecen
Country [66] 0 0
Israel
State/province [66] 0 0
Afula
Country [67] 0 0
Israel
State/province [67] 0 0
Ashkelon
Country [68] 0 0
Israel
State/province [68] 0 0
Haifa
Country [69] 0 0
Israel
State/province [69] 0 0
Jerusalem
Country [70] 0 0
Israel
State/province [70] 0 0
Nahariya
Country [71] 0 0
Israel
State/province [71] 0 0
Petah-Tiqva
Country [72] 0 0
Israel
State/province [72] 0 0
Ramat Gan
Country [73] 0 0
Israel
State/province [73] 0 0
Tel-Aviv
Country [74] 0 0
Italy
State/province [74] 0 0
Bologna
Country [75] 0 0
Italy
State/province [75] 0 0
Cagliari
Country [76] 0 0
Italy
State/province [76] 0 0
Cuneo
Country [77] 0 0
Italy
State/province [77] 0 0
Roma
Country [78] 0 0
Italy
State/province [78] 0 0
Torino
Country [79] 0 0
Italy
State/province [79] 0 0
Varese
Country [80] 0 0
Japan
State/province [80] 0 0
Fukuoka
Country [81] 0 0
Japan
State/province [81] 0 0
Fukuyama
Country [82] 0 0
Japan
State/province [82] 0 0
Gifu
Country [83] 0 0
Japan
State/province [83] 0 0
Kagoshima
Country [84] 0 0
Japan
State/province [84] 0 0
Kanazawa
Country [85] 0 0
Japan
State/province [85] 0 0
Kawachi Nagano
Country [86] 0 0
Japan
State/province [86] 0 0
Kobe City
Country [87] 0 0
Japan
State/province [87] 0 0
Kumamoto-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Kurume
Country [89] 0 0
Japan
State/province [89] 0 0
Kyoto
Country [90] 0 0
Japan
State/province [90] 0 0
Matsumoto
Country [91] 0 0
Japan
State/province [91] 0 0
Matsuyama
Country [92] 0 0
Japan
State/province [92] 0 0
Nagoya
Country [93] 0 0
Japan
State/province [93] 0 0
Niigata
Country [94] 0 0
Japan
State/province [94] 0 0
Okayama
Country [95] 0 0
Japan
State/province [95] 0 0
Sendai-City
Country [96] 0 0
Japan
State/province [96] 0 0
Shibukawa
Country [97] 0 0
Japan
State/province [97] 0 0
Shibuya
Country [98] 0 0
Mexico
State/province [98] 0 0
Aguascalientes
Country [99] 0 0
Mexico
State/province [99] 0 0
Cuernavaca
Country [100] 0 0
Mexico
State/province [100] 0 0
Guadalajara
Country [101] 0 0
Mexico
State/province [101] 0 0
Merida
Country [102] 0 0
Mexico
State/province [102] 0 0
Monterrey
Country [103] 0 0
Netherlands
State/province [103] 0 0
Apeldoorn
Country [104] 0 0
Netherlands
State/province [104] 0 0
Den Haag
Country [105] 0 0
Netherlands
State/province [105] 0 0
Dordrecht
Country [106] 0 0
Netherlands
State/province [106] 0 0
Tilburg
Country [107] 0 0
Norway
State/province [107] 0 0
Oslo
Country [108] 0 0
Poland
State/province [108] 0 0
Brzozow
Country [109] 0 0
Poland
State/province [109] 0 0
Bydgoszcz
Country [110] 0 0
Poland
State/province [110] 0 0
Legnica
Country [111] 0 0
Poland
State/province [111] 0 0
Poznan
Country [112] 0 0
Poland
State/province [112] 0 0
Warszawa
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Dzerzhinsk
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Moscow
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Nizhny Novgorod
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Perm
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Petrozavodsk
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Ryazan
Country [119] 0 0
Russian Federation
State/province [119] 0 0
St-Petersburg
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Syktyvkar
Country [121] 0 0
Spain
State/province [121] 0 0
Badalona
Country [122] 0 0
Spain
State/province [122] 0 0
Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Pamplona
Country [125] 0 0
Spain
State/province [125] 0 0
Pozuelo de Alarcon
Country [126] 0 0
Spain
State/province [126] 0 0
Salamanca
Country [127] 0 0
Spain
State/province [127] 0 0
Valencia
Country [128] 0 0
Sweden
State/province [128] 0 0
Falun
Country [129] 0 0
Sweden
State/province [129] 0 0
Luelå
Country [130] 0 0
Sweden
State/province [130] 0 0
Stockholm
Country [131] 0 0
Turkey
State/province [131] 0 0
Ankara
Country [132] 0 0
Turkey
State/province [132] 0 0
Edirne
Country [133] 0 0
Turkey
State/province [133] 0 0
Istanbul
Country [134] 0 0
Turkey
State/province [134] 0 0
Kayseri
Country [135] 0 0
Turkey
State/province [135] 0 0
Samsun
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Birmingham
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Bristol
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Canterbury
Country [139] 0 0
United Kingdom
State/province [139] 0 0
London
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Manchester
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Nottingham
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Stoke-On-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03301220